Patricia Lugar

Dr. Patricia Lugar

Pediatric Hematology Oncology
1821 Hillandale Rd, 
Durham, NC 
Offers Telehealth
1821 Hillandale Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical Research

Overview

Patricia Lugar is a Pediatric Hematologist Oncology provider in Durham, North Carolina. Dr. Lugar is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. Her top areas of expertise are Chronic Spontaneous Urticaria (CSU), Mast Cell Activation Syndrome (MCAS), Chronic Granulomatous Disease, and Ganglioglioma.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
1821 Hillandale Rd, Durham, NC 27705
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Biological
Study Phase: Phase 3
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Enrollment Status: Completed
Publish Date: March 25, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 2 Less Clinical Trials

22 Total Publications

Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.
Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.
Journal: The Journal of allergy and clinical immunology
Published: April 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lugar's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile